Medical Doctor Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Tian Hao Zhu

Dermatology Castro Valley, CA Medical Doctor

NPI 1033640537 CMS profile 11323010

20400 Lake Chabot Rd Ste 202, Castro Valley, CA 94546

Open in the dashboard

General payments

$9,500

420 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tian Hao Zhu of Castro Valley, CA is reported in the CMS Open Payments database as having received $9,500 across 420 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,340 145
2024 General $3,444 144
2023 General $2,151 94
2022 General $564 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tian Hao Zhu
  • Dermatology median
  • Middle half of Dermatology
  • National median

In program year 2025, general payments to Tian Hao Zhu were reported at $3,340. Among 10,363 Dermatology profiles paid that year, the median was $788 and the middle half received between $207 and $1,974.

Show as a table
Year Tian Hao Zhu Dermatology median Middle half National median
2019 $0 $454 $129–$1,240 $163
2020 $0 $235 $81–$756 $114
2021 $0 $377 $108–$1,108 $132
2022 $564 $514 $143–$1,391 $149
2023 $2,151 $607 $159–$1,674 $160
2024 $3,444 $751 $204–$1,903 $164
2025 $3,340 $788 $207–$1,974 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. AbbVie, Inc. $4,527 195 payments
  2. Incyte Corporation $703 37 payments
  3. Regeneron Healthcare Solutions, Inc. $671 33 payments
  4. LEO Pharma Inc. $525 27 payments
  5. Arcutis Biotherapeutics, Inc. $473 20 payments
  6. Pfizer Inc. $466 20 payments
  7. Genzyme Corporation $379 16 payments
  8. E.R. Squibb & Sons, L.L.C. $374 15 payments
  9. UCB, Inc. $330 14 payments
  10. Janssen Biotech, Inc. $209 14 payments
  11. Other $844 29 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $9,469 417 payments
  2. Education $31 3 payments
Products named General payments · program years 2022–2025
  1. SKYRIZI Immunology $2,975 120 payments
  2. RINVOQ $866 50 payments
  3. OPZELURA $703 37 payments
  4. SKYRIZI Immunology $655 23 payments
  5. DUPIXENT $621 26 payments
  6. CIBINQO $466 20 payments
  7. Zoryve $408 17 payments
  8. ADBRY $386 26 payments
  9. SOTYKTU $374 15 payments
  10. Bimzelx $330 14 payments
  11. Other $2,568 109 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

552

Median for Dermatology: 534

Drug cost

$333,338

Median for Dermatology: $67,151

Branded share of claims

7.1%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Skyrizi Pen Risankizumab-Rzaa Brand 16 $318,766
Clobetasol Propionate Generic 70 $4,067
Fluorouracil Generic 45 $3,645
Betamethasone Dipropionate Generic 37 $1,748
Ketoconazole Generic 79 $1,167
Clindamycin Phosphate Generic 24 $972
Triamcinolone Acetonide Generic 63 $639
Fluocinonide Generic 18 $562
Clotrimazole Generic 24 $498
Ciclopirox Generic 11 $372

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$639,520

Of which drugs: $2,721

Medicare patients

629

Average age 77

Services billed

4,221

295 women, 334 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 40%
Diabetes 29%
Chronic kidney disease 28%
Ischemic heart disease 23%
Atrial fibrillation 21%
Heart failure 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 13 19 $15

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 16 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
  • AbbVie, Inc. $1,587
$1,587 16 —
RINVOQ
  • AbbVie, Inc. $411
$411 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $236
$236 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $120
  • GENZYME CORPORATION $115
$235 — —
TREMFYA
  • Janssen Biotech, Inc. $195
$195 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 16 in the dashboard with a free account

Records

420 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Dermatology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record